Background We investigated effects of mesenchymal stem cells (MSC) or low-flow
extracorporeal life support (ECLS) as adjunctive treatments for acute respiratory distress …

Rationale: Early post injury mitigation strategies in ARDS are in short supply. Treatments
with allogeneic stromal cells are administered after ARDS develops, require specialized …

Acute lung injury (ALI), and its more severe form, acute respiratory distress syndrome
(ARDS), are syndromes of acute hypoxemic respiratory failure resulting from a variety of …

Pulmonary edema is a hallmark of acute respiratory distress syndrome (ARDS). Smoke
inhalation causes ARDS, significantly increasing the mortality of burn patients …

Acute lung injury/acute respiratory distress syndrome (ALI/ARDS) is a major cause of global
morbidity and mortality. Mesenchymal stem cells (MSC) have shown promise in treating …

Rationale: Mesenchymal stromal cell (MSC) therapy is a promising intervention for acute
respiratory distress syndrome (ARDS), although trials to date have not investigated its use …

Background Normal lung healing is impaired when lung contusion (LC) is followed by
hemorrhagic shock (HS), and chronic stress (CS). Mesenchymal stem cells (MSCs) are …

Acute respiratory distress syndrome (ARDS) is the result of a wide variety of disorders, which
can be associated with different clinical disorders or systemic diseases directly affecting the …

This study tested whether human umbilical cord–derived mesenchymal stem cells
(HUCDMSCs) treatment effectively protected the rat lung against acute respiratory distress …

Mesenchymal stem cells (MSCs) are a promising form of therapy for acute respiratory
distress syndrome (ARDS). The objective of this study was twofold:(a) to characterize …